Business Wire

CAPCOM

Share
Capcom Achieves Record-High Net Sales and Sixth Consecutive Year of Record-High Profits Driven by Digital Contents Business in Consolidated Results for the Year Ended March 2023

Capcom Co., Ltd. (TOKYO:9697) today announced that in its consolidated business results (Japan GAAP – unaudited) for the fiscal year ended March 31, 2023, net sales were 125,930 million yen (up 14.4 % from the previous fiscal year), operating income was 50,812 million yen (up 18.4 % from the previous fiscal year), ordinary income was 51,369 million yen (up 15.9 % from the previous fiscal year), and net income attributable to owners of the parent was 36,737 million yen (up 12.9 % from the previous fiscal year).

During the fiscal year ended March 31, 2023, Capcom’s core Digital Contents business delivered annual sales of 41.7 million units for its home video game software, marking a year-over-year increase. The company achieved this with the release of major new titles in its flagship series, including Resident Evil 4 and Monster Hunter Rise: Sunbreak, as well as through pursuing catalog title sales digitally. Further, the company expanded earnings by leveraging these major brands in movies, character merchandise, and eSports, while promoting efficient operations at stores and new store formats in its Arcade Operations business, and utilizing its IP in its Amusement Equipments businesses. As a result, Capcom achieved record-high net sales, the sixth consecutive year of record-high profit at all levels, and its tenth consecutive year of operating income growth.

Moving forward, for the fiscal year ending March 31, 2024, Capcom anticipates net sales of 140,000 million yen and operating income of 56,000 million yen, which would result in eleven consecutive years of operating income growth and seven consecutive years of record high profit at all levels.

1. Consolidated financial results of the year ended March 31, 2023 (April 1, 2022 - March 31, 2023)

 

Net sales

Operating income

Ordinary income

Net income attributable to owners of the parent

Earnings per share

 

million yen

million yen

million yen

million yen

yen

Year ended March 31, 2023

125,930

50,812

51,369

36,737

174.73

Year ended March 31, 2022

110,054

42,909

44,330

32,553

152.48

2. Earnings forecast for the fiscal year ending March 31, 2024

 

Net sales

Operating income

Ordinary income

Net income attributable to owners of the parent

Earnings per share

 

million yen

million yen

million yen

million yen

yen

Year ending March 31, 2024

140,000

56,000

56,000

40,000

191.28

Note: Capcom discloses only full year business forecasts, as it manages its business performance on an annual basis.

ABOUT CAPCOM

Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/

Forward-looking Statements

Strategies, plans, outlooks and other statements that are not historical facts are based on assumptions that use information currently available and reasonable judgments. Actual performance may be significantly different from these statements for a number of reasons. In the entertainment industry, which includes Capcom, performance may be highly volatile because of diverging user needs and other changes in market conditions. Factors that can affect Capcom’s performance include: (1) the number of hit titles and sales volume in the Home Video Game Business, which accounts for the majority of sales; (2) progress in developing home video games; (3) consumer demand for home video game consoles; (4) sales outside Japan; (5) changes in stock prices and exchange rates; (6) alliances with other companies concerning product development, sales and other operations; and (7) changes in market conditions; (8) natural disasters, disease outbreaks, economic crises and other unforeseeable events. Please note that this is not a complete list of factors that can influence Capcom’s operating results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005387/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release

Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian

1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release

In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new

Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release

Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye